top of page

The CEO of Jasper Therapeutics on c-KIT inhibition

Ronald Martell describes Jasper's subcu programs for urticaria and how the company also continues to test its antibody as an alternative to harsh chemotherapy preconditioning during stem cell transplants.



Comentarios


Join the BiotechTV mailing list

Thanks for subscribing!

bottom of page